A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 127,500 shares of AKBA stock, worth $262,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,500
Previous 91,800 38.89%
Holding current value
$262,650
Previous $93,000 80.65%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.86 - $1.63 $113,034 - $214,239
131,435 Added 157.91%
214,669 $218,000
Q1 2024

May 15, 2024

SELL
$1.27 - $2.24 $133,807 - $236,006
-105,360 Reduced 55.87%
83,234 $152,000
Q4 2023

Feb 14, 2024

BUY
$0.8 - $1.28 $150,875 - $241,400
188,594 New
188,594 $233,000
Q2 2023

Aug 14, 2023

BUY
$0.51 - $1.43 $492 - $1,379
965 New
965 $0
Q4 2022

Feb 14, 2023

SELL
$0.25 - $0.58 $71,944 - $166,910
-287,777 Reduced 95.55%
13,397 $7,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $0.46 $46,838 - $71,819
-156,129 Reduced 34.14%
301,174 $95,000
Q2 2022

Aug 15, 2022

BUY
$0.32 - $0.67 $737 - $1,545
2,306 Added 0.51%
457,303 $162,000
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $79,848 - $324,937
-110,900 Reduced 19.6%
454,997 $326,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $963,661 - $1.42 Million
426,399 Added 305.67%
565,897 $1.28 Million
Q3 2021

Nov 15, 2021

SELL
$2.35 - $3.88 $153,271 - $253,061
-65,222 Reduced 31.86%
139,498 $402,000
Q2 2021

Aug 16, 2021

SELL
$2.83 - $4.2 $473,727 - $703,059
-167,395 Reduced 44.98%
204,720 $775,000
Q1 2021

May 17, 2021

SELL
$2.92 - $5.06 $1.78 Million - $3.08 Million
-608,146 Reduced 62.04%
372,115 $1.26 Million
Q4 2020

Feb 16, 2021

BUY
$2.22 - $3.78 $1.25 Million - $2.13 Million
563,132 Added 135.0%
980,261 $2.75 Million
Q3 2020

Nov 16, 2020

BUY
$2.39 - $13.08 $880,444 - $4.82 Million
368,387 Added 755.79%
417,129 $1.05 Million
Q2 2020

Aug 14, 2020

SELL
$6.67 - $13.58 $1.14 Million - $2.32 Million
-170,539 Reduced 77.77%
48,742 $662,000
Q1 2020

May 15, 2020

SELL
$4.1 - $10.24 $2.82 Million - $7.05 Million
-688,939 Reduced 75.86%
219,281 $1.66 Million
Q4 2019

Feb 14, 2020

BUY
$3.16 - $6.73 $1.7 Million - $3.62 Million
537,470 Added 144.97%
908,220 $5.74 Million
Q3 2019

Nov 14, 2019

BUY
$3.55 - $5.4 $952,173 - $1.45 Million
268,218 Added 261.59%
370,750 $1.45 Million
Q2 2019

Aug 14, 2019

BUY
$4.1 - $8.05 $287,352 - $564,192
70,086 Added 216.01%
102,532 $497,000
Q1 2019

May 15, 2019

SELL
$5.41 - $8.73 $7.61 Million - $12.3 Million
-1,407,296 Reduced 97.75%
32,446 $0
Q4 2018

Feb 14, 2019

BUY
$5.39 - $9.15 $2.41 Million - $4.1 Million
447,966 Added 45.17%
1,439,742 $7.96 Million
Q3 2018

Nov 13, 2018

BUY
$7.44 - $10.65 $2.76 Million - $3.96 Million
371,440 Added 59.88%
991,776 $0
Q2 2018

Aug 10, 2018

BUY
$9.15 - $11.34 $3.58 Million - $4.43 Million
391,022 Added 170.52%
620,336 $0
Q1 2018

May 11, 2018

BUY
$9.53 - $15.68 $2.19 Million - $3.6 Million
229,314 New
229,314 $2.19 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $379M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.